Welcome to our dedicated page for Dentsply Sirona news (Ticker: XRAY), a resource for investors and traders seeking the latest updates and insights on Dentsply Sirona stock.
DENTSPLY SIRONA Inc. (Nasdaq: XRAY) regularly issues news and updates that shed light on its role as the world’s largest diversified manufacturer of professional dental products and technologies. Company press releases cover topics such as strategic partnerships, leadership changes, financial results and portfolio decisions, giving investors and dental professionals insight into how the business is evolving.
Recent news has highlighted Dentsply Sirona’s focus on connected dentistry and technology-enabled solutions. The company has announced expanded and renewed distribution partnerships in the United States that provide access to its dental technology portfolio, including systems and imaging solutions referenced in those agreements. These announcements emphasize integrated ecosystems that connect devices, software and services from scanning through design and manufacturing workflows.
News items also address corporate strategy and performance, including quarterly financial results and the introduction of a Return-to-Growth action plan. In these updates, Dentsply Sirona outlines priorities such as putting customers at the center, strengthening the U.S. business, and evolving operations to support innovation and training. Leadership appointments in commercial, finance and regional roles are frequently reported, reflecting the company’s efforts to align its organization with these priorities.
Other press releases describe decisions about the Wellspect Healthcare business, dividend declarations, participation in investor conferences and the conclusion of an SEC Division of Enforcement investigation without enforcement action. Together, these news items provide a detailed view of how Dentsply Sirona manages its portfolio, governance and capital allocation. Readers interested in XRAY can use this news feed to follow developments in connected dentistry, strategic partnerships, governance actions and financial communications from the company.
Dentsply Sirona (Nasdaq: XRAY) appointed Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28, 2026. The hire is intended to strengthen commercial execution, deepen customer relationships and accelerate growth across the Americas. Bezjak joins from Zimmer Biomet, brings more than 20 years of commercial leadership and experience leading multi‑billion‑dollar organizations, and has a track record of commercial transformations and revenue and operating income growth. Management highlights his experience in orthopedics and customer‑first field execution as aligned with the company’s goal to elevate service to the dental community.
Dentsply Sirona (Nasdaq: XRAY) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 3:00 p.m. PT (6:00 p.m. ET).
Dan Scavilla, President and CEO, will discuss the company's Connected Dentistry portfolio, dental market trends, and progress on its return-to-growth strategy. A live audio webcast and replay will be available via the company's Investors website at https://investor.dentsplysirona.com.
DENTSPLY SIRONA (Nasdaq: XRAY) announced a quarterly cash dividend of $0.16 per share, equal to an indicated annual rate of $0.64 per share. The dividend is payable on January 9, 2026 to shareholders of record as of December 26, 2025.
Dentsply Sirona (Nasdaq: XRAY) reported Q3 2025 results on November 6, 2025: net sales $904 million (down 5.0% reported, down 8.0% constant currency). GAAP net loss $427 million (loss per share $2.14); non-cash impairment charges were $263 million net of tax. On a non-GAAP basis, adjusted EPS $0.37, adjusted gross margin 52.6%, and adjusted EBITDA margin 18.4%. Operating cash flow was $79 million in Q3 and cash on hand was $363 million as of Sept 30, 2025.
The company launched a Return-to-Growth action plan, announced leadership changes including a CFO transition and a new Chief Transformation Officer, and revised FY25 guidance to $3.6B–$3.7B net sales and ~$1.60 adjusted EPS.
Dentsply Sirona (Nasdaq: XRAY) will host a third-quarter fiscal 2025 investor conference call and live webcast on Thursday, November 6, 2025 at 8:30 AM ET to review Q3 results. A press release and a presentation with summary financial information will be posted on the company's Investors website before the call. The live webcast and a replay will be available at https://investor.dentsplysirona.com. Registered participants may join the call via the provided registration link.
Dentsply Sirona (NASDAQ:XRAY), the world's largest diversified dental manufacturer, has appointed Aldo M. Denti as Executive Vice President and Chief Commercial Officer (CCO), effective October 6, 2025.
Denti brings over 25 years of experience in Medical Device and Consumer Health sectors, most recently serving as Company Group Chairman, Global Orthopedics at Johnson & Johnson Medtech. The appointment aims to enhance customer focus by aligning Global Business Units and Commercial Organizations, streamlining operations and delivery processes.
CEO Daniel Scavilla highlighted that Denti will lead global sales strategy and execution to drive growth, profitability, and customer satisfaction across all regions. The new CCO role is designed to strengthen collaboration across business units and unlock synergies.
Dentsply Sirona (Nasdaq: XRAY) has announced its decision to retain Wellspect Healthcare as a subsidiary following a comprehensive strategic review initiated in February 2025. The company determined that keeping Wellspect within its portfolio would create more value for stockholders than other alternatives, including potential sale options.
Wellspect, a leading provider of bladder and bowel care products with a 40-year history, has demonstrated strong performance with mid-single digit growth in 2024. The business operates in the continence care market, which has an estimated $2 billion addressable market. CEO Dan Scavilla emphasized Wellspect's position as a category leader with strong cash flow generation and significant market potential.
Dentsply Sirona (NASDAQ:XRAY), a dental products company, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 2:35 PM ET and the Baird Global Healthcare Conference on September 9 at 1:25 PM ET.
Investors can access live audio webcasts and replays of both presentations through the Investors section of Dentsply Sirona's website.
Dentsply Sirona (NASDAQ:XRAY) reported challenging Q2 2025 results with net sales declining to $936 million, down 4.9% (6.7% in constant currency). The company posted a GAAP net loss of ($0.22) per share, impacted by a significant $214 million non-cash impairment charge. Despite revenue challenges, adjusted earnings per share increased to $0.52 from $0.49 year-over-year.
Notable developments include a $550 million debt offering and key leadership changes, with Dan Scavilla appointed as CEO and Matt Garth as CFO. The company maintained its FY25 outlook, projecting net sales of $3.60-3.70 billion and adjusted EPS of $1.80-2.00. Margin performance showed improvement with adjusted EBITDA margin reaching 21.1%, up from 17.5% in Q2 2024.
Dentsply Sirona (NASDAQ: XRAY) has appointed Daniel Scavilla as its new President and CEO, effective August 1, 2025, succeeding Simon Campion. Scavilla, a current board member with over 30 years of experience in medical technology, previously served as CEO of Globus Medical and held leadership roles at Johnson & Johnson.
The company also released preliminary Q2 2025 results, expecting net sales of approximately $935 million and adjusted EPS between $0.50-$0.52. Dentsply Sirona has reaffirmed its full-year 2025 outlook previously provided in May 2025, with final Q2 results to be reported on August 7, 2025.